nodes	percent_of_prediction	percent_of_DWPC	metapath
Dofetilide—CYP3A4—prostate cancer	0.27	1	CbGaD
Dofetilide—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0851	0.207	CbGbCtD
Dofetilide—CYP3A4—Bicalutamide—prostate cancer	0.0447	0.109	CbGbCtD
Dofetilide—CYP3A4—Estramustine—prostate cancer	0.0415	0.101	CbGbCtD
Dofetilide—CYP3A4—Abiraterone—prostate cancer	0.037	0.09	CbGbCtD
Dofetilide—CYP3A4—Flutamide—prostate cancer	0.037	0.09	CbGbCtD
Dofetilide—CYP3A4—Cabazitaxel—prostate cancer	0.0274	0.0666	CbGbCtD
Dofetilide—CYP3A4—Estrone—prostate cancer	0.0268	0.0651	CbGbCtD
Dofetilide—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0239	0.058	CbGbCtD
Dofetilide—CYP3A4—Conjugated Estrogens—prostate cancer	0.0175	0.0426	CbGbCtD
Dofetilide—CYP3A4—Mitoxantrone—prostate cancer	0.0159	0.0387	CbGbCtD
Dofetilide—CYP3A4—Estradiol—prostate cancer	0.0154	0.0374	CbGbCtD
Dofetilide—CYP3A4—Prednisone—prostate cancer	0.0132	0.0321	CbGbCtD
Dofetilide—CYP3A4—Etoposide—prostate cancer	0.01	0.0244	CbGbCtD
Dofetilide—CYP3A4—Docetaxel—prostate cancer	0.00919	0.0223	CbGbCtD
Dofetilide—CYP3A4—Doxorubicin—prostate cancer	0.00685	0.0166	CbGbCtD
Dofetilide—Rosiglitazone—ACSL4—prostate cancer	0.00501	0.74	CrCbGaD
Dofetilide—KCNK2—prostate gland—prostate cancer	0.0041	0.277	CbGeAlD
Dofetilide—CYP3A4—urine—prostate cancer	0.00198	0.134	CbGeAlD
Dofetilide—KCNK2—testis—prostate cancer	0.00181	0.122	CbGeAlD
Dofetilide—KCNK2—lymph node—prostate cancer	0.00131	0.0885	CbGeAlD
Dofetilide—KCNH2—prostate gland—prostate cancer	0.00115	0.0774	CbGeAlD
Dofetilide—KCNH2—seminal vesicle—prostate cancer	0.000968	0.0654	CbGeAlD
Dofetilide—Rosiglitazone—CYP2A6—prostate cancer	0.000842	0.124	CrCbGaD
Dofetilide—KCNH2—renal system—prostate cancer	0.00078	0.0527	CbGeAlD
Dofetilide—KCNH2—urethra—prostate cancer	0.000767	0.0518	CbGeAlD
Dofetilide—Rosiglitazone—CYP2C19—prostate cancer	0.000592	0.0875	CrCbGaD
Dofetilide—KCNH2—bone marrow—prostate cancer	0.00059	0.0399	CbGeAlD
Dofetilide—KCNH2—testis—prostate cancer	0.000504	0.0341	CbGeAlD
Dofetilide—CYP3A4—renal system—prostate cancer	0.000484	0.0327	CbGeAlD
Dofetilide—KCNH2—lymph node—prostate cancer	0.000366	0.0247	CbGeAlD
Dofetilide—Dronedarone—CYP3A4—prostate cancer	0.000328	0.0484	CrCbGaD
Dofetilide—Palpitations—Estradiol—prostate cancer	0.000254	0.00115	CcSEcCtD
Dofetilide—Pain—Goserelin—prostate cancer	0.000253	0.00114	CcSEcCtD
Dofetilide—Nausea—Bicalutamide—prostate cancer	0.000253	0.00114	CcSEcCtD
Dofetilide—Loss of consciousness—Estradiol—prostate cancer	0.000253	0.00114	CcSEcCtD
Dofetilide—Cardiac arrest—Prednisone—prostate cancer	0.000252	0.00114	CcSEcCtD
Dofetilide—Cough—Estradiol—prostate cancer	0.000251	0.00113	CcSEcCtD
Dofetilide—Pain—Conjugated Estrogens—prostate cancer	0.000251	0.00113	CcSEcCtD
Dofetilide—Angina pectoris—Capecitabine—prostate cancer	0.000251	0.00113	CcSEcCtD
Dofetilide—Hypertension—Estradiol—prostate cancer	0.000248	0.00112	CcSEcCtD
Dofetilide—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000246	0.00111	CcSEcCtD
Dofetilide—Chest pain—Estradiol—prostate cancer	0.000245	0.00111	CcSEcCtD
Dofetilide—Arthralgia—Estradiol—prostate cancer	0.000245	0.00111	CcSEcCtD
Dofetilide—Anxiety—Estradiol—prostate cancer	0.000244	0.0011	CcSEcCtD
Dofetilide—Gastrointestinal pain—Goserelin—prostate cancer	0.000242	0.00109	CcSEcCtD
Dofetilide—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.00024	0.00108	CcSEcCtD
Dofetilide—Dizziness—Ethinyl Estradiol—prostate cancer	0.000238	0.00107	CcSEcCtD
Dofetilide—Oedema—Estradiol—prostate cancer	0.000235	0.00106	CcSEcCtD
Dofetilide—Abdominal pain—Goserelin—prostate cancer	0.000234	0.00106	CcSEcCtD
Dofetilide—Cough—Mitoxantrone—prostate cancer	0.000234	0.00106	CcSEcCtD
Dofetilide—Acute coronary syndrome—Docetaxel—prostate cancer	0.000234	0.00106	CcSEcCtD
Dofetilide—Myocardial infarction—Docetaxel—prostate cancer	0.000232	0.00105	CcSEcCtD
Dofetilide—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000232	0.00105	CcSEcCtD
Dofetilide—Hypertension—Mitoxantrone—prostate cancer	0.000231	0.00105	CcSEcCtD
Dofetilide—Shock—Estradiol—prostate cancer	0.000231	0.00104	CcSEcCtD
Dofetilide—Arthralgia—Mitoxantrone—prostate cancer	0.000228	0.00103	CcSEcCtD
Dofetilide—Chest pain—Mitoxantrone—prostate cancer	0.000228	0.00103	CcSEcCtD
Dofetilide—Anxiety—Mitoxantrone—prostate cancer	0.000227	0.00103	CcSEcCtD
Dofetilide—Hyperhidrosis—Estradiol—prostate cancer	0.000227	0.00102	CcSEcCtD
Dofetilide—Rash—Ethinyl Estradiol—prostate cancer	0.000227	0.00102	CcSEcCtD
Dofetilide—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000226	0.00102	CcSEcCtD
Dofetilide—Acute coronary syndrome—Capecitabine—prostate cancer	0.000226	0.00102	CcSEcCtD
Dofetilide—Headache—Ethinyl Estradiol—prostate cancer	0.000225	0.00102	CcSEcCtD
Dofetilide—Myocardial infarction—Capecitabine—prostate cancer	0.000225	0.00102	CcSEcCtD
Dofetilide—Urinary tract infection—Capecitabine—prostate cancer	0.000223	0.00101	CcSEcCtD
Dofetilide—Oedema—Mitoxantrone—prostate cancer	0.000219	0.000988	CcSEcCtD
Dofetilide—Back pain—Etoposide—prostate cancer	0.000215	0.000974	CcSEcCtD
Dofetilide—Shock—Mitoxantrone—prostate cancer	0.000215	0.000972	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000214	0.000966	CcSEcCtD
Dofetilide—Nausea—Ethinyl Estradiol—prostate cancer	0.000214	0.000965	CcSEcCtD
Dofetilide—Cardiac failure—Epirubicin—prostate cancer	0.000212	0.00096	CcSEcCtD
Dofetilide—Asthenia—Goserelin—prostate cancer	0.000212	0.00096	CcSEcCtD
Dofetilide—Insomnia—Estradiol—prostate cancer	0.000212	0.000959	CcSEcCtD
Dofetilide—Cerebrovascular accident—Epirubicin—prostate cancer	0.000212	0.000956	CcSEcCtD
Dofetilide—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000211	0.000955	CcSEcCtD
Dofetilide—Paraesthesia—Estradiol—prostate cancer	0.000211	0.000952	CcSEcCtD
Dofetilide—Asthenia—Conjugated Estrogens—prostate cancer	0.00021	0.00095	CcSEcCtD
Dofetilide—Bradycardia—Capecitabine—prostate cancer	0.00021	0.000947	CcSEcCtD
Dofetilide—Oedema peripheral—Docetaxel—prostate cancer	0.000209	0.000947	CcSEcCtD
Dofetilide—Dyspnoea—Estradiol—prostate cancer	0.000209	0.000945	CcSEcCtD
Dofetilide—Migraine—Epirubicin—prostate cancer	0.000204	0.000922	CcSEcCtD
Dofetilide—Oedema peripheral—Capecitabine—prostate cancer	0.000203	0.000917	CcSEcCtD
Dofetilide—Diarrhoea—Goserelin—prostate cancer	0.000202	0.000915	CcSEcCtD
Dofetilide—Acute coronary syndrome—Prednisone—prostate cancer	0.000201	0.00091	CcSEcCtD
Dofetilide—Pain—Estradiol—prostate cancer	0.000201	0.000907	CcSEcCtD
Dofetilide—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000201	0.000906	CcSEcCtD
Dofetilide—Myocardial infarction—Prednisone—prostate cancer	0.0002	0.000905	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000199	0.0009	CcSEcCtD
Dofetilide—Cardiac arrest—Epirubicin—prostate cancer	0.000197	0.000891	CcSEcCtD
Dofetilide—Cardiac failure—Doxorubicin—prostate cancer	0.000197	0.000889	CcSEcCtD
Dofetilide—Paraesthesia—Mitoxantrone—prostate cancer	0.000196	0.000887	CcSEcCtD
Dofetilide—Loss of consciousness—Etoposide—prostate cancer	0.000196	0.000885	CcSEcCtD
Dofetilide—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000196	0.000885	CcSEcCtD
Dofetilide—Dizziness—Goserelin—prostate cancer	0.000196	0.000884	CcSEcCtD
Dofetilide—Dyspnoea—Mitoxantrone—prostate cancer	0.000195	0.000881	CcSEcCtD
Dofetilide—Cough—Etoposide—prostate cancer	0.000194	0.000879	CcSEcCtD
Dofetilide—Dizziness—Conjugated Estrogens—prostate cancer	0.000194	0.000876	CcSEcCtD
Dofetilide—Hypertension—Etoposide—prostate cancer	0.000192	0.000869	CcSEcCtD
Dofetilide—Gastrointestinal pain—Estradiol—prostate cancer	0.000192	0.000867	CcSEcCtD
Dofetilide—Arrhythmia—Docetaxel—prostate cancer	0.00019	0.000859	CcSEcCtD
Dofetilide—Chest pain—Etoposide—prostate cancer	0.00019	0.000857	CcSEcCtD
Dofetilide—Migraine—Doxorubicin—prostate cancer	0.000189	0.000854	CcSEcCtD
Dofetilide—Pain—Mitoxantrone—prostate cancer	0.000187	0.000845	CcSEcCtD
Dofetilide—Bradycardia—Prednisone—prostate cancer	0.000187	0.000844	CcSEcCtD
Dofetilide—Rash—Goserelin—prostate cancer	0.000187	0.000843	CcSEcCtD
Dofetilide—Dermatitis—Goserelin—prostate cancer	0.000186	0.000843	CcSEcCtD
Dofetilide—Abdominal pain—Estradiol—prostate cancer	0.000185	0.000838	CcSEcCtD
Dofetilide—Headache—Goserelin—prostate cancer	0.000185	0.000838	CcSEcCtD
Dofetilide—Rash—Conjugated Estrogens—prostate cancer	0.000185	0.000835	CcSEcCtD
Dofetilide—Dermatitis—Conjugated Estrogens—prostate cancer	0.000185	0.000835	CcSEcCtD
Dofetilide—Arrhythmia—Capecitabine—prostate cancer	0.000184	0.000831	CcSEcCtD
Dofetilide—Headache—Conjugated Estrogens—prostate cancer	0.000184	0.00083	CcSEcCtD
Dofetilide—Cardiac arrest—Doxorubicin—prostate cancer	0.000182	0.000825	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	0.000181	0.00239	CbGpPWpGaD
Dofetilide—Influenza—Epirubicin—prostate cancer	0.000179	0.00081	CcSEcCtD
Dofetilide—Back pain—Docetaxel—prostate cancer	0.000179	0.000809	CcSEcCtD
Dofetilide—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000179	0.000808	CcSEcCtD
Dofetilide—CYP3A4—Tamoxifen metabolism—CYP1B1—prostate cancer	0.000176	0.00232	CbGpPWpGaD
Dofetilide—Nausea—Goserelin—prostate cancer	0.000176	0.000794	CcSEcCtD
Dofetilide—Hyperhidrosis—Etoposide—prostate cancer	0.000176	0.000794	CcSEcCtD
Dofetilide—Angina pectoris—Epirubicin—prostate cancer	0.000175	0.000789	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7B1—prostate cancer	0.000174	0.00231	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—ESR2—prostate cancer	0.000174	0.0023	CbGpPWpGaD
Dofetilide—Nausea—Conjugated Estrogens—prostate cancer	0.000174	0.000787	CcSEcCtD
Dofetilide—CYP3A4—Estrogen metabolism—COMT—prostate cancer	0.000174	0.0023	CbGpPWpGaD
Dofetilide—Back pain—Capecitabine—prostate cancer	0.000173	0.000784	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—TH—prostate cancer	0.000173	0.00229	CbGpPWpGaD
Dofetilide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	0.000173	0.00229	CbGpPWpGaD
Dofetilide—Abdominal pain—Mitoxantrone—prostate cancer	0.000173	0.000781	CcSEcCtD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	0.000172	0.00228	CbGpPWpGaD
Dofetilide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.000171	0.00226	CbGpPWpGaD
Dofetilide—Asthenia—Estradiol—prostate cancer	0.000168	0.000761	CcSEcCtD
Dofetilide—Syncope—Docetaxel—prostate cancer	0.000166	0.00075	CcSEcCtD
Dofetilide—Influenza—Doxorubicin—prostate cancer	0.000166	0.000749	CcSEcCtD
Dofetilide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	0.000166	0.00219	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—PLCB2—prostate cancer	0.000164	0.00217	CbGpPWpGaD
Dofetilide—Arrhythmia—Prednisone—prostate cancer	0.000164	0.000741	CcSEcCtD
Dofetilide—Palpitations—Docetaxel—prostate cancer	0.000164	0.000739	CcSEcCtD
Dofetilide—Paraesthesia—Etoposide—prostate cancer	0.000163	0.000738	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—EGR1—prostate cancer	0.000163	0.00215	CbGpPWpGaD
Dofetilide—Loss of consciousness—Docetaxel—prostate cancer	0.000163	0.000735	CcSEcCtD
Dofetilide—Dyspnoea—Etoposide—prostate cancer	0.000162	0.000733	CcSEcCtD
Dofetilide—Cough—Docetaxel—prostate cancer	0.000162	0.00073	CcSEcCtD
Dofetilide—Angina pectoris—Doxorubicin—prostate cancer	0.000162	0.00073	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.000161	0.00213	CbGpPWpGaD
Dofetilide—Syncope—Capecitabine—prostate cancer	0.000161	0.000727	CcSEcCtD
Dofetilide—Diarrhoea—Estradiol—prostate cancer	0.00016	0.000725	CcSEcCtD
Dofetilide—Hypertension—Docetaxel—prostate cancer	0.00016	0.000722	CcSEcCtD
Dofetilide—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	0.000159	0.0021	CbGpPWpGaD
Dofetilide—Palpitations—Capecitabine—prostate cancer	0.000158	0.000716	CcSEcCtD
Dofetilide—Chest pain—Docetaxel—prostate cancer	0.000158	0.000712	CcSEcCtD
Dofetilide—Arthralgia—Docetaxel—prostate cancer	0.000158	0.000712	CcSEcCtD
Dofetilide—Loss of consciousness—Capecitabine—prostate cancer	0.000158	0.000712	CcSEcCtD
Dofetilide—Asthenia—Mitoxantrone—prostate cancer	0.000157	0.000709	CcSEcCtD
Dofetilide—KCNH2—Neuronal System—SLC22A1—prostate cancer	0.000157	0.00207	CbGpPWpGaD
Dofetilide—Cough—Capecitabine—prostate cancer	0.000156	0.000707	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	0.000156	0.00206	CbGpPWpGaD
Dofetilide—Pain—Etoposide—prostate cancer	0.000155	0.000703	CcSEcCtD
Dofetilide—Urinary tract infection—Epirubicin—prostate cancer	0.000155	0.000702	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—GJA1—prostate cancer	0.000155	0.00205	CbGpPWpGaD
Dofetilide—Dizziness—Estradiol—prostate cancer	0.000155	0.000701	CcSEcCtD
Dofetilide—Hypertension—Capecitabine—prostate cancer	0.000155	0.000699	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—AR—prostate cancer	0.000154	0.00203	CbGpPWpGaD
Dofetilide—Sweating—Epirubicin—prostate cancer	0.000153	0.000692	CcSEcCtD
Dofetilide—Arthralgia—Capecitabine—prostate cancer	0.000153	0.00069	CcSEcCtD
Dofetilide—Chest pain—Capecitabine—prostate cancer	0.000153	0.00069	CcSEcCtD
Dofetilide—Anxiety—Capecitabine—prostate cancer	0.000152	0.000687	CcSEcCtD
Dofetilide—Oedema—Docetaxel—prostate cancer	0.000151	0.000683	CcSEcCtD
Dofetilide—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	0.000151	0.00199	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	0.00015	0.00198	CbGpPWpGaD
Dofetilide—Diarrhoea—Mitoxantrone—prostate cancer	0.00015	0.000676	CcSEcCtD
Dofetilide—KCNH2—Neuronal System—GNG5—prostate cancer	0.000149	0.00197	CbGpPWpGaD
Dofetilide—Gastrointestinal pain—Etoposide—prostate cancer	0.000149	0.000672	CcSEcCtD
Dofetilide—Shock—Docetaxel—prostate cancer	0.000149	0.000672	CcSEcCtD
Dofetilide—Rash—Estradiol—prostate cancer	0.000148	0.000669	CcSEcCtD
Dofetilide—Dermatitis—Estradiol—prostate cancer	0.000148	0.000668	CcSEcCtD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	0.000148	0.00195	CbGpPWpGaD
Dofetilide—Headache—Estradiol—prostate cancer	0.000147	0.000664	CcSEcCtD
Dofetilide—Oedema—Capecitabine—prostate cancer	0.000146	0.000661	CcSEcCtD
Dofetilide—Bradycardia—Epirubicin—prostate cancer	0.000146	0.00066	CcSEcCtD
Dofetilide—Angioedema—Prednisone—prostate cancer	0.000146	0.000659	CcSEcCtD
Dofetilide—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	0.000146	0.00193	CbGpPWpGaD
Dofetilide—CYP3A4—Irinotecan Pathway—APC—prostate cancer	0.000144	0.00191	CbGpPWpGaD
Dofetilide—Shock—Capecitabine—prostate cancer	0.000144	0.000651	CcSEcCtD
Dofetilide—Abdominal pain—Etoposide—prostate cancer	0.000144	0.00065	CcSEcCtD
Dofetilide—Urinary tract infection—Doxorubicin—prostate cancer	0.000144	0.00065	CcSEcCtD
Dofetilide—Syncope—Prednisone—prostate cancer	0.000143	0.000647	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	0.000142	0.00188	CbGpPWpGaD
Dofetilide—Sweating—Doxorubicin—prostate cancer	0.000142	0.000641	CcSEcCtD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	0.000141	0.00187	CbGpPWpGaD
Dofetilide—Hyperhidrosis—Capecitabine—prostate cancer	0.000141	0.000639	CcSEcCtD
Dofetilide—Oedema peripheral—Epirubicin—prostate cancer	0.000141	0.000639	CcSEcCtD
Dofetilide—Loss of consciousness—Prednisone—prostate cancer	0.00014	0.000634	CcSEcCtD
Dofetilide—Nausea—Estradiol—prostate cancer	0.000139	0.00063	CcSEcCtD
Dofetilide—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	0.000139	0.00183	CbGpPWpGaD
Dofetilide—Hypertension—Prednisone—prostate cancer	0.000138	0.000623	CcSEcCtD
Dofetilide—Rash—Mitoxantrone—prostate cancer	0.000138	0.000623	CcSEcCtD
Dofetilide—Dermatitis—Mitoxantrone—prostate cancer	0.000138	0.000622	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000138	0.000622	CcSEcCtD
Dofetilide—Headache—Mitoxantrone—prostate cancer	0.000137	0.000619	CcSEcCtD
Dofetilide—Insomnia—Docetaxel—prostate cancer	0.000137	0.000618	CcSEcCtD
Dofetilide—Arthralgia—Prednisone—prostate cancer	0.000136	0.000614	CcSEcCtD
Dofetilide—Paraesthesia—Docetaxel—prostate cancer	0.000136	0.000613	CcSEcCtD
Dofetilide—Anxiety—Prednisone—prostate cancer	0.000135	0.000612	CcSEcCtD
Dofetilide—Bradycardia—Doxorubicin—prostate cancer	0.000135	0.000611	CcSEcCtD
Dofetilide—Dyspnoea—Docetaxel—prostate cancer	0.000135	0.000609	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—IL10—prostate cancer	0.000135	0.00178	CbGpPWpGaD
Dofetilide—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	0.000133	0.00176	CbGpPWpGaD
Dofetilide—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000133	0.000602	CcSEcCtD
Dofetilide—KCNH2—Neuronal System—ACHE—prostate cancer	0.000133	0.00175	CbGpPWpGaD
Dofetilide—Insomnia—Capecitabine—prostate cancer	0.000132	0.000598	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	0.000132	0.00175	CbGpPWpGaD
Dofetilide—Paraesthesia—Capecitabine—prostate cancer	0.000131	0.000594	CcSEcCtD
Dofetilide—Oedema peripheral—Doxorubicin—prostate cancer	0.000131	0.000591	CcSEcCtD
Dofetilide—Asthenia—Etoposide—prostate cancer	0.00013	0.00059	CcSEcCtD
Dofetilide—Dyspnoea—Capecitabine—prostate cancer	0.00013	0.000589	CcSEcCtD
Dofetilide—Oedema—Prednisone—prostate cancer	0.00013	0.000589	CcSEcCtD
Dofetilide—Nausea—Mitoxantrone—prostate cancer	0.00013	0.000587	CcSEcCtD
Dofetilide—Pain—Docetaxel—prostate cancer	0.000129	0.000584	CcSEcCtD
Dofetilide—Shock—Prednisone—prostate cancer	0.000128	0.000579	CcSEcCtD
Dofetilide—Arrhythmia—Epirubicin—prostate cancer	0.000128	0.000579	CcSEcCtD
Dofetilide—KCNH2—Neuronal System—PRKACB—prostate cancer	0.000127	0.00168	CbGpPWpGaD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	0.000126	0.00167	CbGpPWpGaD
Dofetilide—Hyperhidrosis—Prednisone—prostate cancer	0.000126	0.000569	CcSEcCtD
Dofetilide—Pain—Capecitabine—prostate cancer	0.000125	0.000565	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.000125	0.00165	CbGpPWpGaD
Dofetilide—Diarrhoea—Etoposide—prostate cancer	0.000124	0.000562	CcSEcCtD
Dofetilide—Gastrointestinal pain—Docetaxel—prostate cancer	0.000124	0.000558	CcSEcCtD
Dofetilide—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—prostate cancer	0.000123	0.00162	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	0.000121	0.0016	CbGpPWpGaD
Dofetilide—Back pain—Epirubicin—prostate cancer	0.000121	0.000546	CcSEcCtD
Dofetilide—Dizziness—Etoposide—prostate cancer	0.00012	0.000543	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.00012	0.00158	CbGpPWpGaD
Dofetilide—Gastrointestinal pain—Capecitabine—prostate cancer	0.00012	0.000541	CcSEcCtD
Dofetilide—Abdominal pain—Docetaxel—prostate cancer	0.000119	0.00054	CcSEcCtD
Dofetilide—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000119	0.000537	CcSEcCtD
Dofetilide—Arrhythmia—Doxorubicin—prostate cancer	0.000119	0.000536	CcSEcCtD
Dofetilide—Insomnia—Prednisone—prostate cancer	0.000118	0.000533	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	0.000118	0.00156	CbGpPWpGaD
Dofetilide—Paraesthesia—Prednisone—prostate cancer	0.000117	0.000529	CcSEcCtD
Dofetilide—KCNK2—Neuronal System—MDM2—prostate cancer	0.000117	0.00154	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	0.000116	0.00154	CbGpPWpGaD
Dofetilide—Abdominal pain—Capecitabine—prostate cancer	0.000116	0.000523	CcSEcCtD
Dofetilide—Rash—Etoposide—prostate cancer	0.000115	0.000518	CcSEcCtD
Dofetilide—Dermatitis—Etoposide—prostate cancer	0.000115	0.000518	CcSEcCtD
Dofetilide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000114	0.00151	CbGpPWpGaD
Dofetilide—Headache—Etoposide—prostate cancer	0.000114	0.000515	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.000113	0.0015	CbGpPWpGaD
Dofetilide—Syncope—Epirubicin—prostate cancer	0.000112	0.000506	CcSEcCtD
Dofetilide—Back pain—Doxorubicin—prostate cancer	0.000112	0.000505	CcSEcCtD
Dofetilide—Palpitations—Epirubicin—prostate cancer	0.00011	0.000499	CcSEcCtD
Dofetilide—Loss of consciousness—Epirubicin—prostate cancer	0.00011	0.000496	CcSEcCtD
Dofetilide—Cough—Epirubicin—prostate cancer	0.000109	0.000493	CcSEcCtD
Dofetilide—Asthenia—Docetaxel—prostate cancer	0.000108	0.00049	CcSEcCtD
Dofetilide—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	0.000108	0.00143	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	0.000108	0.00143	CbGpPWpGaD
Dofetilide—Nausea—Etoposide—prostate cancer	0.000108	0.000488	CcSEcCtD
Dofetilide—Hypertension—Epirubicin—prostate cancer	0.000108	0.000487	CcSEcCtD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	0.000107	0.00142	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	0.000107	0.00141	CbGpPWpGaD
Dofetilide—Gastrointestinal pain—Prednisone—prostate cancer	0.000107	0.000482	CcSEcCtD
Dofetilide—Arthralgia—Epirubicin—prostate cancer	0.000106	0.000481	CcSEcCtD
Dofetilide—Chest pain—Epirubicin—prostate cancer	0.000106	0.000481	CcSEcCtD
Dofetilide—Anxiety—Epirubicin—prostate cancer	0.000106	0.000479	CcSEcCtD
Dofetilide—Asthenia—Capecitabine—prostate cancer	0.000105	0.000474	CcSEcCtD
Dofetilide—Syncope—Doxorubicin—prostate cancer	0.000104	0.000468	CcSEcCtD
Dofetilide—Diarrhoea—Docetaxel—prostate cancer	0.000103	0.000467	CcSEcCtD
Dofetilide—Abdominal pain—Prednisone—prostate cancer	0.000103	0.000466	CcSEcCtD
Dofetilide—Palpitations—Doxorubicin—prostate cancer	0.000102	0.000462	CcSEcCtD
Dofetilide—Oedema—Epirubicin—prostate cancer	0.000102	0.000461	CcSEcCtD
Dofetilide—CYP3A4—Biological oxidations—GSTM3—prostate cancer	0.000102	0.00135	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	0.000102	0.00135	CbGpPWpGaD
Dofetilide—Loss of consciousness—Doxorubicin—prostate cancer	0.000102	0.000459	CcSEcCtD
Dofetilide—Cough—Doxorubicin—prostate cancer	0.000101	0.000456	CcSEcCtD
Dofetilide—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	0.0001	0.00133	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	0.0001	0.00133	CbGpPWpGaD
Dofetilide—Shock—Epirubicin—prostate cancer	0.0001	0.000453	CcSEcCtD
Dofetilide—Diarrhoea—Capecitabine—prostate cancer	0.0001	0.000452	CcSEcCtD
Dofetilide—Dizziness—Docetaxel—prostate cancer	9.99e-05	0.000452	CcSEcCtD
Dofetilide—Hypertension—Doxorubicin—prostate cancer	9.97e-05	0.000451	CcSEcCtD
Dofetilide—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	9.91e-05	0.00131	CbGpPWpGaD
Dofetilide—Hyperhidrosis—Epirubicin—prostate cancer	9.85e-05	0.000445	CcSEcCtD
Dofetilide—Chest pain—Doxorubicin—prostate cancer	9.84e-05	0.000445	CcSEcCtD
Dofetilide—Arthralgia—Doxorubicin—prostate cancer	9.84e-05	0.000445	CcSEcCtD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	9.83e-05	0.0013	CbGpPWpGaD
Dofetilide—Anxiety—Doxorubicin—prostate cancer	9.8e-05	0.000443	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	9.76e-05	0.00129	CbGpPWpGaD
Dofetilide—Dizziness—Capecitabine—prostate cancer	9.67e-05	0.000437	CcSEcCtD
Dofetilide—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	9.66e-05	0.00128	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—NAT1—prostate cancer	9.66e-05	0.00128	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	9.64e-05	0.00127	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	9.55e-05	0.00126	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	9.53e-05	0.00126	CbGpPWpGaD
Dofetilide—Rash—Docetaxel—prostate cancer	9.53e-05	0.000431	CcSEcCtD
Dofetilide—Dermatitis—Docetaxel—prostate cancer	9.52e-05	0.00043	CcSEcCtD
Dofetilide—Headache—Docetaxel—prostate cancer	9.47e-05	0.000428	CcSEcCtD
Dofetilide—Oedema—Doxorubicin—prostate cancer	9.43e-05	0.000426	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	9.42e-05	0.00125	CbGpPWpGaD
Dofetilide—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	9.39e-05	0.00124	CbGpPWpGaD
Dofetilide—Asthenia—Prednisone—prostate cancer	9.35e-05	0.000423	CcSEcCtD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	9.3e-05	0.00123	CbGpPWpGaD
Dofetilide—Musculoskeletal discomfort—Epirubicin—prostate cancer	9.28e-05	0.00042	CcSEcCtD
Dofetilide—Shock—Doxorubicin—prostate cancer	9.28e-05	0.000419	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—CREBBP—prostate cancer	9.26e-05	0.00122	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—COMT—prostate cancer	9.24e-05	0.00122	CbGpPWpGaD
Dofetilide—Rash—Capecitabine—prostate cancer	9.22e-05	0.000417	CcSEcCtD
Dofetilide—Insomnia—Epirubicin—prostate cancer	9.22e-05	0.000417	CcSEcCtD
Dofetilide—Dermatitis—Capecitabine—prostate cancer	9.21e-05	0.000417	CcSEcCtD
Dofetilide—Headache—Capecitabine—prostate cancer	9.16e-05	0.000414	CcSEcCtD
Dofetilide—Paraesthesia—Epirubicin—prostate cancer	9.15e-05	0.000414	CcSEcCtD
Dofetilide—Hyperhidrosis—Doxorubicin—prostate cancer	9.12e-05	0.000412	CcSEcCtD
Dofetilide—Dyspnoea—Epirubicin—prostate cancer	9.09e-05	0.000411	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	9.02e-05	0.00119	CbGpPWpGaD
Dofetilide—Nausea—Docetaxel—prostate cancer	8.97e-05	0.000406	CcSEcCtD
Dofetilide—Diarrhoea—Prednisone—prostate cancer	8.92e-05	0.000403	CcSEcCtD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	8.9e-05	0.00118	CbGpPWpGaD
Dofetilide—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	8.83e-05	0.00117	CbGpPWpGaD
Dofetilide—Pain—Epirubicin—prostate cancer	8.71e-05	0.000394	CcSEcCtD
Dofetilide—Nausea—Capecitabine—prostate cancer	8.69e-05	0.000393	CcSEcCtD
Dofetilide—Dizziness—Prednisone—prostate cancer	8.62e-05	0.000389	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	8.6e-05	0.00114	CbGpPWpGaD
Dofetilide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	8.59e-05	0.000388	CcSEcCtD
Dofetilide—Insomnia—Doxorubicin—prostate cancer	8.53e-05	0.000385	CcSEcCtD
Dofetilide—Paraesthesia—Doxorubicin—prostate cancer	8.47e-05	0.000383	CcSEcCtD
Dofetilide—Dyspnoea—Doxorubicin—prostate cancer	8.41e-05	0.00038	CcSEcCtD
Dofetilide—Gastrointestinal pain—Epirubicin—prostate cancer	8.33e-05	0.000377	CcSEcCtD
Dofetilide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	8.29e-05	0.0011	CbGpPWpGaD
Dofetilide—Rash—Prednisone—prostate cancer	8.22e-05	0.000371	CcSEcCtD
Dofetilide—Dermatitis—Prednisone—prostate cancer	8.21e-05	0.000371	CcSEcCtD
Dofetilide—Headache—Prednisone—prostate cancer	8.16e-05	0.000369	CcSEcCtD
Dofetilide—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	8.1e-05	0.00107	CbGpPWpGaD
Dofetilide—Pain—Doxorubicin—prostate cancer	8.06e-05	0.000364	CcSEcCtD
Dofetilide—Abdominal pain—Epirubicin—prostate cancer	8.06e-05	0.000364	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	8.01e-05	0.00106	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	7.92e-05	0.00105	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	7.9e-05	0.00104	CbGpPWpGaD
Dofetilide—Nausea—Prednisone—prostate cancer	7.74e-05	0.00035	CcSEcCtD
Dofetilide—Gastrointestinal pain—Doxorubicin—prostate cancer	7.71e-05	0.000349	CcSEcCtD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	7.64e-05	0.00101	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	7.59e-05	0.001	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	7.51e-05	0.000993	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	7.49e-05	0.000991	CbGpPWpGaD
Dofetilide—Abdominal pain—Doxorubicin—prostate cancer	7.45e-05	0.000337	CcSEcCtD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	7.41e-05	0.000979	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—CXCL8—prostate cancer	7.36e-05	0.000973	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	7.32e-05	0.000968	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	7.31e-05	0.000967	CbGpPWpGaD
Dofetilide—Asthenia—Epirubicin—prostate cancer	7.31e-05	0.00033	CcSEcCtD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	7.24e-05	0.000958	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	7.22e-05	0.000954	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	7.14e-05	0.000944	CbGpPWpGaD
Dofetilide—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	7.12e-05	0.000941	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	7.05e-05	0.000931	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—CASP3—prostate cancer	7.04e-05	0.000931	CbGpPWpGaD
Dofetilide—Diarrhoea—Epirubicin—prostate cancer	6.97e-05	0.000315	CcSEcCtD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	6.97e-05	0.000921	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	6.89e-05	0.000911	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	6.79e-05	0.000897	CbGpPWpGaD
Dofetilide—Asthenia—Doxorubicin—prostate cancer	6.77e-05	0.000306	CcSEcCtD
Dofetilide—Dizziness—Epirubicin—prostate cancer	6.74e-05	0.000305	CcSEcCtD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	6.49e-05	0.000858	CbGpPWpGaD
Dofetilide—Diarrhoea—Doxorubicin—prostate cancer	6.45e-05	0.000292	CcSEcCtD
Dofetilide—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	6.45e-05	0.000852	CbGpPWpGaD
Dofetilide—Rash—Epirubicin—prostate cancer	6.43e-05	0.00029	CcSEcCtD
Dofetilide—Dermatitis—Epirubicin—prostate cancer	6.42e-05	0.00029	CcSEcCtD
Dofetilide—Headache—Epirubicin—prostate cancer	6.38e-05	0.000289	CcSEcCtD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	6.36e-05	0.00084	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—EP300—prostate cancer	6.31e-05	0.000834	CbGpPWpGaD
Dofetilide—Dizziness—Doxorubicin—prostate cancer	6.24e-05	0.000282	CcSEcCtD
Dofetilide—CYP3A4—Biological oxidations—GSTA3—prostate cancer	6.22e-05	0.000823	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	6.16e-05	0.000814	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	6.14e-05	0.000812	CbGpPWpGaD
Dofetilide—Nausea—Epirubicin—prostate cancer	6.05e-05	0.000274	CcSEcCtD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—VEGFA—prostate cancer	5.98e-05	0.00079	CbGpPWpGaD
Dofetilide—Rash—Doxorubicin—prostate cancer	5.95e-05	0.000269	CcSEcCtD
Dofetilide—Dermatitis—Doxorubicin—prostate cancer	5.94e-05	0.000268	CcSEcCtD
Dofetilide—Headache—Doxorubicin—prostate cancer	5.91e-05	0.000267	CcSEcCtD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	5.87e-05	0.000776	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.79e-05	0.000765	CbGpPWpGaD
Dofetilide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.75e-05	0.000761	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.69e-05	0.000753	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.69e-05	0.000753	CbGpPWpGaD
Dofetilide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.68e-05	0.000751	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.62e-05	0.000742	CbGpPWpGaD
Dofetilide—Nausea—Doxorubicin—prostate cancer	5.6e-05	0.000253	CcSEcCtD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.59e-05	0.000738	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.55e-05	0.000733	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.48e-05	0.000724	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.4e-05	0.000714	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTA1—prostate cancer	5.35e-05	0.000708	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTO1—prostate cancer	5.29e-05	0.0007	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—NAT2—prostate cancer	5.29e-05	0.0007	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	5.22e-05	0.00069	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	5.22e-05	0.00069	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	5.07e-05	0.000671	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	5e-05	0.000662	CbGpPWpGaD
Dofetilide—KCNH2—Neuronal System—MDM2—prostate cancer	4.94e-05	0.000653	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.72e-05	0.000624	CbGpPWpGaD
Dofetilide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.67e-05	0.000617	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.65e-05	0.000615	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.44e-05	0.000587	CbGpPWpGaD
Dofetilide—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.39e-05	0.00058	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—HPGDS—prostate cancer	4.23e-05	0.000559	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	4.2e-05	0.000556	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	4.15e-05	0.000548	CbGpPWpGaD
Dofetilide—KCNH2—SIDS Susceptibility Pathways—IL6—prostate cancer	4.13e-05	0.000546	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTT1—prostate cancer	4.1e-05	0.000542	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	4.06e-05	0.000536	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.89e-05	0.000514	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.88e-05	0.000514	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.83e-05	0.000506	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.7e-05	0.000489	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.45e-05	0.000456	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.4e-05	0.00045	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.27e-05	0.000432	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.22e-05	0.000426	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.17e-05	0.000419	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—NCOA1—prostate cancer	3.12e-05	0.000412	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	3.07e-05	0.000406	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	3.03e-05	0.000401	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.97e-05	0.000392	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—COMT—prostate cancer	2.86e-05	0.000378	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.84e-05	0.000376	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.82e-05	0.000373	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.81e-05	0.000371	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.61e-05	0.000346	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.58e-05	0.000341	CbGpPWpGaD
Dofetilide—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.48e-05	0.000328	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HAO1—prostate cancer	2.45e-05	0.000323	CbGpPWpGaD
Dofetilide—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.44e-05	0.000323	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PSAT1—prostate cancer	1.99e-05	0.000264	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GRHL1—prostate cancer	1.99e-05	0.000264	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CSAD—prostate cancer	1.99e-05	0.000264	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—TST—prostate cancer	1.99e-05	0.000264	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ADI1—prostate cancer	1.99e-05	0.000264	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CBR1—prostate cancer	1.99e-05	0.000264	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CKMT2—prostate cancer	1.85e-05	0.000245	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GRHPR—prostate cancer	1.85e-05	0.000245	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.85e-05	0.000245	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.85e-05	0.000245	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—RFK—prostate cancer	1.74e-05	0.00023	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTM3—prostate cancer	1.74e-05	0.00023	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PGAM2—prostate cancer	1.74e-05	0.00023	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AOX1—prostate cancer	1.74e-05	0.00023	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NAGLU—prostate cancer	1.74e-05	0.00023	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.74e-05	0.00023	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.74e-05	0.00023	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.65e-05	0.000218	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AMACR—prostate cancer	1.65e-05	0.000218	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—DEGS1—prostate cancer	1.65e-05	0.000218	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NAT1—prostate cancer	1.65e-05	0.000218	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.65e-05	0.000218	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.58e-05	0.000208	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.4e-05	0.000186	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HPGD—prostate cancer	1.4e-05	0.000186	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.32e-05	0.000175	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.28e-05	0.00017	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—MTAP—prostate cancer	1.28e-05	0.00017	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.25e-05	0.000165	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.25e-05	0.000165	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ACSL4—prostate cancer	1.19e-05	0.000158	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.19e-05	0.000158	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ARG2—prostate cancer	1.15e-05	0.000151	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PHGDH—prostate cancer	1.15e-05	0.000151	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—UMPS—prostate cancer	1.15e-05	0.000151	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—LDHB—prostate cancer	1.12e-05	0.000148	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.1e-05	0.000146	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—UCP3—prostate cancer	1.06e-05	0.000141	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—TCN2—prostate cancer	1.06e-05	0.000141	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PDHA1—prostate cancer	1.06e-05	0.000141	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTA3—prostate cancer	1.06e-05	0.000141	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.02e-05	0.000134	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.02e-05	0.000134	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.74e-06	0.000129	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTA4—prostate cancer	9.74e-06	0.000129	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTA2—prostate cancer	9.49e-06	0.000125	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ABCG5—prostate cancer	9.37e-06	0.000124	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SULT1A1—prostate cancer	9.37e-06	0.000124	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTA1—prostate cancer	9.15e-06	0.000121	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTO1—prostate cancer	9.05e-06	0.00012	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HSD3B2—prostate cancer	9.05e-06	0.00012	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NAT2—prostate cancer	9.05e-06	0.00012	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PLCB2—prostate cancer	8.68e-06	0.000115	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—LRP2—prostate cancer	8.68e-06	0.000115	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.68e-06	0.000115	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—P4HB—prostate cancer	8.51e-06	0.000112	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC22A1—prostate cancer	8.28e-06	0.000109	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SULT2A1—prostate cancer	8.07e-06	0.000107	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—MED12—prostate cancer	7.94e-06	0.000105	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GNG5—prostate cancer	7.87e-06	0.000104	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NCOA3—prostate cancer	7.59e-06	0.0001	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—HPGDS—prostate cancer	7.24e-06	9.57e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP2C19—prostate cancer	7.19e-06	9.51e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ACHE—prostate cancer	7.02e-06	9.28e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTT1—prostate cancer	7.02e-06	9.28e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.94e-06	9.17e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.75e-06	8.92e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PRKACB—prostate cancer	6.71e-06	8.87e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.64e-06	8.78e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NCOA2—prostate cancer	6.33e-06	8.37e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—SLC5A5—prostate cancer	6.04e-06	7.98e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.9e-06	7.8e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NQO1—prostate cancer	5.83e-06	7.71e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—TH—prostate cancer	5.75e-06	7.6e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.59e-06	7.39e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GGT1—prostate cancer	5.42e-06	7.16e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NCOA1—prostate cancer	5.33e-06	7.05e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.26e-06	6.95e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—RXRA—prostate cancer	5.07e-06	6.71e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—COMT—prostate cancer	4.89e-06	6.46e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTP1—prostate cancer	4.86e-06	6.43e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ITPR1—prostate cancer	4.79e-06	6.33e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—TYMS—prostate cancer	4.52e-06	5.98e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—GSTM1—prostate cancer	4.47e-06	5.91e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—LPL—prostate cancer	4.39e-06	5.8e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.24e-06	5.6e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—ERCC2—prostate cancer	4.2e-06	5.56e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—MTHFR—prostate cancer	3.95e-06	5.22e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PPARA—prostate cancer	3.88e-06	5.12e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CAV1—prostate cancer	3.64e-06	4.82e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.32e-06	4.39e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—INS—prostate cancer	3.14e-06	4.15e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—CREBBP—prostate cancer	3.08e-06	4.07e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.92e-06	3.86e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—NOS3—prostate cancer	2.76e-06	3.64e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.54e-06	3.36e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PTGS2—prostate cancer	2.52e-06	3.33e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PTEN—prostate cancer	2.2e-06	2.91e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—EP300—prostate cancer	2.1e-06	2.77e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.55e-06	2.05e-05	CbGpPWpGaD
Dofetilide—CYP3A4—Metabolism—AKT1—prostate cancer	1.27e-06	1.67e-05	CbGpPWpGaD
